Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Product Highlight - QTERN

29 Nov 2019
• Superior HbA1c reduction vs DPP4i +Met or SGLT2i +Met1

• Nearly 2x patients achieved HbA1c <7%1

• Established safety profile of DPP4i with additional benefits of SGLT2i3,5-8

• Extends oral therapy with a once daily tablet4-7



References:
1. Rostenstock J, et al. Diabetes Care 2015; 38(3):376·383.
2. T. Vilsboll, et al. Dapagliflozin plus Saxagliptin shows noninferior HbA1c reductions vs insulin Glargine in patients with Type 2 Diabetes Inadequately.
3. Qtern Malaysia Prescribing Information, AstraZeneca, 2019.
4. Lokhandwala T, et al. J Med Econ. 2016: 19: 203-12.
5. Del Prato S, et al. Diabetes Obes Metab 2018; 20: 1542·1546.
6. Matthaei S, et al. Diabetes Care. 2015: 38: 2018-2024.
7. Bailey CJ, et aI. Lancet 2010; 37: 2233-33.
8. Del Prato S, et al. Diabetes Obes Metab 2015;17: 581-90.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.